Previous issuances
Previous issuances
Use our timeline to chart all vaccine bond issuances in capital markets around the world since their launch in London in 2006.
Since the inaugural benchmark issuance in 2006, IFFIm bonds have been issued in Japan, the UK, Australia and in the Eurobond market. IFFIm also has issued in the Islamic finance market.
Our timeline charts all previous issuances.
2022
October 2022
Fixed rate vaccine bonds
In October, IFFIm returned to the US dollar market with US$ 500 million, 3-year fixed rate bond to provide Gavi with immediately available funding to support routine immunisation in lower-income countries, reaching nearly half the world’s children.
July 2022
United Kingdom
In July, IFFIm returned to the sterling bond market with a £250 million 3-year, fixed-rate vaccine bond that will help finance Gavi’s core immunisation programmes, including reaching millions of “zero dose” children who have never received a single vaccine. The transaction was oversubscribed, despite a volatile market backdrop. Barclays and TD Securities were lead managers for the transaction.
2021
November 2021
Fixed rate vaccine bonds
In November, IFFIm increased by US$ 250 million the 1% 5-year vaccine bond it issued in April 2021, bringing the total to US$ 1 billion. Proceeds will provide immediately available funding for Gavi’s routine immunisation programmes in low-income countries. This bond increase occurred on the 15th anniversary of IFFIm’s first vaccine bond issue in November 2006.
April 2021
Fixed rate vaccine bonds
In April, IFFIm priced US$ 750 million, 5-year fixed rate vaccine bonds to provide Gavi, the Vaccine Alliance with immediately available funding to support routine immunisation in lower-income countries, reaching nearly half the world’s children. The issuance, IFFIm’s second largest ever, will also accelerate the availability of critical funding for the Gavi COVAX Advance Market Commitment (or AMC).
2020
October 2020
Fixed rate benchmark
In October, IFFIm priced a US$500 million, 3-year fixed rate benchmark Vaccine Bonds that will provide Gavi, the Vaccine Alliance, flexible funding for its core immunisation programmes and efforts to develop and distribute eventual COVID-19 vaccines to countries around the world, particularly the poorest. This is IFFIm’s first US$ benchmark bond since its US$300 million 3-year floating rate bond in November 2017.
July 2020
Norway (CEPI)
In July, IFFIm issued a NOK 2 billion in zero coupon amortising Vaccine Bonds to accelerate the availability of financing for urgent COVID-19 vaccine research and development by the Coalition for Epidemic Preparedness Innovations (CEPI). The Vaccine Bonds will leverage that funding against a 10-year, NOK 2 billion commitment from the Kingdom of Norway announced in March through Gavi, the Vaccine Alliance to CEPI. This transaction marks IFFIm’s 36th issuance and its second bond in Norwegian kroner following a 2019 Vaccine Bond that raised NOK 600 million for CEPI.
2019
July 2019
Norway (CEPI)
In July 2019, IFFIm raised NOK 600 million (US$ 65.7 million equivalent), marking its 35th issuance and its first bond in Norwegian krone. The transaction, jointly managed by Skandinaviska Enskilda Banken (SEB) and the Toronto-Dominion Bank, will frontload a pledge from the Government of Norway to Gavi in support of research and development of new vaccines by the Coalition for Epidemic Preparedness Innovation (CEPI). Japan’s Dai-ichi Life is a major purchaser and IFFIm’s first institutional investor in Japan, joined by two Norwegian institutions, Kommunalbanken (KBN) and Norwegian pension fund MP.
April 2019
Sukuk
In April 2019, IFFIm raised US$ 50 million in a private placement of 3-year Sukuk that complies with Islamic financing principles, was issued by IFFIm, with IsDB as the sole investor. The First Abu Dhabi Bank (FAB) acted as placement agent on the transaction.
2017
November 2017
Global benchmark
IFFIm returns again to the international US dollar benchmark market, raising US$ 300 million in a transaction jointly led by Citi, Crédit Agricole and Goldman Sachs International. This re-establishes IFFIm as regular borrower in the market following its US$ 500 million 3-year floating rate note issued in October 2016.
2016
October 2016
Global benchmark
IFFIm’s return to the international US$ benchmark market, raising US$ 500 million in a transaction jointly led by Citi, Deutsche Bank and J.P. Morgan. It is IFFIm’s second floating rate offer and its fifth benchmark since 2006.
2015
September 2015
Sukuk
IFFIm issued a second sukuk, raising US$ 200 million with a 3-year socially responsible investment that complies with Islamic law. The sukuk was oversubscribed, maturing on 29 September 2018, carrying a quarterly coupon of +14 basis points over 3-month USD LIBOR.
2014
November 2014
Sukuk
IFFIm entered the sukuk market for the first time, raising US$ 500 million with a 3-year socially responsible investment that complies with Islamic law. The sukuk was oversubscribed, maturing on 4 December 2017, carrying a quarterly coupon of +15 basis points over 3-month USD LIBOR.
2013
June 2013
Global benchmark
IFFIm issues its largest financing since its inaugural benchmark, raising US$ 700 million in a transaction jointly led by Daiwa Securities Group and Deutsche Bank. It is IFFIm’s first floating rate offer, and its first benchmark since 2010 (fourth overall).
March 2013
Japan
Daiwa Securities Group sponsors its fifth highly successful issuance of IFFIm vaccine bonds, raising US$ 139 million with 5-year notes denominated in Turkish lira and South African rand. The total amount arranged by Daiwa now is about US$ 1.35 billion equivalent.
2012
Summer 2012
Japan
IFFIm makes a strong return to the capital markets, raising the equivalent of US$ 137.2 million for Gavi programmes with two uridashi retail bond offerings. The first was arranged by HSBC and raised US$ 98.4 million. Investors were offered a 3-year fixed-rate South African rand-denominated bond, a 4.5-year fixed-rate Australian dollar-denominated bond and a 15-year South African rand-denominated deep-discount bond. The second uridashi was a 5-year Australian dollar-denominated bond underwritten by J.P. Morgan that raised US$ 38.76 million.
2011
September 2011
Japan
In September 2011, IFFIm completed its first J.P. Morgan-arranged issue of vaccine bonds, raising the equivalent of US$ 169.4 million for Gavi programmes. The issuance included tranches in three currencies, comprising a 5-year South African rand tranche in the amount of ZAR 650 million (US$ 91 million equivalent); a 3-year Brazilian real tranche in the amount of BRL 105 million (US$ 66 million equivalent); and a 4-year Australian dollar tranche in the amount of AUD 12 million (US$ 12.4 million equivalent).
March 2011
Japan
In March 2011, IFFIm completed the fourth issue of IFFIm's vaccine bonds arranged by Daiwa, raising BRL 371 million (US$ 225 million). The previous, highly successful issues were completed in March 2008, February 2009 and March 2010. The total amount of IFFIm's vaccine bonds arranged by Daiwa is now over US$ 1 billion equivalent.
2010
November 2010
Australia
In November, 2010, IFFIm's inaugural Kangaroo bond was successfully completed. The A$ 400 million (US$ 395 million), five-year bond issue was lead managed by the Commonwealth Bank of Australia and RBC Capital Markets. The notes were placed globally, across a broad range of over 20 investors.
October 2010
Eurobond Market
In October 2010, IFFIm raised A$ 35 million (US$ 34 million) in a private placement of five-year Eurobonds arranged for IFFIm by the TD Securities.
June 2010
Japan
In June 2010, IFFIm raised US$ 101 million equivalent in three uridashi offerings in Japan. The multi-tranche transaction includes Australian dollar and South African rand denominated bonds and the first IFFIm bond denominated in Brazilian real and settled in Japanese Yen. This offering was arranged by HSBC Securities (Japan).
March 2010
Japan
In March 2010, IFFIm raised ZAR 2.5 billion (US$ 320.5 million) in a three year uridashi offering in Japan. This was the third issue arranged for IFFIm by the Daiwa Securities Group, and was IFFIm's largest South African rand denominated issuance to date.
2009
June 2009
Japan
In June, 2009, a multi-tranche uridashi offering of IFFIm vaccine bonds, arranged by HSBC Securities (Japan), was sold through a group of 19 securities distributors and offered to Japanese investors online. The total amount of the offering was approximately US$ 130 million and was composed of three tranches: (i) a four-year Australian dollar fixed rate tranche; (ii) a four-year South African rand fixed rate tranche, and (iii) a 15 year South African rand deep discount tranche.
May 2009
United Kingdom
IFFIm issued its first bonds in the sterling market in May 2009. The two tranche transaction raised an aggregate £266 million (approximately US$ 400 million) and was split between a £250 million fixed rate tranche for institutional investors and a £16,227,290 zero coupon tranche for retail investors. The institutional tranche was lead managed by HSBC and Royal Bank of Scotland. The retail tranche was packaged as the HSBC Vaccine Investment Plan and HSBC Individual Savings Account (ISA).
May 2009
Japan
On 26 May 2009, IFFIm completed a multi-tranche uridashi offering in Japan. The total amount of the offering was US$ 142.9 million made up of two tranches, one in US dollars and the other in Australian dollars. Both tranches are due 25 May 2012. The offering was arranged by Mitsubishi UFJ Securities Co., Ltd.
February 2009
Japan
An offering to Japanese retail investors in February 2009 raised US$ 429 million equivalent. Investors were given the opportunity and choice of investing in "vaccine bonds" denominated in three currencies: South African rand, New Zealand dollars and Australian dollars. The currencies were selected based on investor demand. This offering for the Japanese market was arranged by Daiwa Securities SMBC Co. Ltd., the wholesale securities firm under Daiwa Securities Group, and distributed by Daiwa Securities to Japanese investors.
2008
March 2008
Japan
Japanese investors welcomed the launch in March 2008 of IFFIm's debut offering in the Japanese retail market, a R 1.7 billion (US$ 223 million) two year uridashi issue. The "vaccine bonds" were arranged by Daiwa Securities SMBC Co. Ltd., the wholesale securities firm under Daiwa Securities Group, and distributed by Daiwa Securities to Japanese investors.
2006
November 2006
Inaugural offering
IFFIm's inaugural bonds were issued in London on 14 November 2006 and raised US$ 1 billion. The bonds were priced comparably to other sovereign/supranational issuers and were bought by a broad range of investors - both geographically and by investor type - including several central banks, pension funds, fund managers, and insurance companies. Deutsche Bank and Goldman Sachs lead-managed this inaugural bond issue.
*Individuals who have supported the IFFIm initiative include His Holiness Pope Benedict XVI; Her Majesty Queen Rania Al-Abdullah of Jordan; Cardinal Renato Raffaele Martino; Archbishop of Canterbury, Dr Rowan Williams; Chief Rabbi, Dr Jonathan Sacks; Iqbal Khan of the Muslim Council of Britain; Ramesh Khalidi of the Hindu Forum; Indrajit Singh OBE of the Sikh Council of Britain as well as Bono and Bob Geldof.
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.